| 产品名称： | NCI-H660 |
|---|---|
| 商品货号： | TS211265 |
| Organism： | Homo sapiens, human |
| Tissue： | prostate; derived from the metastatic site: lymph node |
| Cell Type： | epithelial neuroendocrine |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | floating and attached clusters |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | stage E, small cell carcinoma |
| Age： | 63 years adult |
| Gender： | male |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Derived from metastatic site, lymph node |
| Clinical Data： | 63 years adult Caucasian male |
| Receptor Expression： | atrial natriuretic peptide (ANP), expressed |
| HeLa Markers： | N |
| Comments： | While NCI-H660 has the appearance and many of the properties of small cell carcinoma, there are also differences. NCI-H660 expresses elevated levels of L-dopa carboxylase and bombesin-like immunoreactivity. The cells express functional atrial natriuretic peptide (ANP) receptors, but ANP addition produces no detectable change in the cells growth pattern. |
| Complete Growth Medium： | HITES medium supplemented with 5% fetal bovine serum
|
| Subculturing： | Add medium as the cell density increases. Shake flask to dislodge attached cells. Single cells are often dead and clusters are viable. Subculture when there are numerous, healthy-appearing clusters present in suspension.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium, 40%; xa0fetal bovine serum, 50%; DMSO, 10%.
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 12 D13S317: 8 D16S539: 11 D5S818: 11 D7S820: 8,10 THO1: 7,9.3 TPOX: 8 vWA: 17 |
| Name of Depositor： | AF Gazdar, JD Minna |
| Deposited As： | Homo sapiens |
| References： | Lai SL, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15: 225-232, 1995. PubMed: 7762988 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Johnson BE, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl. Cancer Inst. 81: 1223-1228, 1989. PubMed: 2569043 NCI-H660 was originally described as a small cell lung carcinoma PubMed: 2985257, subsequently it was correctly identified as an extrapulmonary small cell carcinoma originating in the prostate gland PubMed: 2569043, 7762988. The line was derived by A. F. Gazdar, H. K. Oie, J. D. Minna and associates from a lymph node metastasis taken from a patient prior to therapy. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | NCI-H660 |
|---|---|
| 商品货号： | TS211265 |
| Organism： | Homo sapiens, human |
| Tissue： | prostate; derived from the metastatic site: lymph node |
| Cell Type： | epithelial neuroendocrine |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | floating and attached clusters |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | stage E, small cell carcinoma |
| Age： | 63 years adult |
| Gender： | male |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Derived from metastatic site, lymph node |
| Clinical Data： | 63 years adult Caucasian male |
| Receptor Expression： | atrial natriuretic peptide (ANP), expressed |
| HeLa Markers： | N |
| Comments： | While NCI-H660 has the appearance and many of the properties of small cell carcinoma, there are also differences. NCI-H660 expresses elevated levels of L-dopa carboxylase and bombesin-like immunoreactivity. The cells express functional atrial natriuretic peptide (ANP) receptors, but ANP addition produces no detectable change in the cells growth pattern. |
| Complete Growth Medium： | HITES medium supplemented with 5% fetal bovine serum
|
| Subculturing： | Add medium as the cell density increases. Shake flask to dislodge attached cells. Single cells are often dead and clusters are viable. Subculture when there are numerous, healthy-appearing clusters present in suspension.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium, 40%; xa0fetal bovine serum, 50%; DMSO, 10%.
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 12 D13S317: 8 D16S539: 11 D5S818: 11 D7S820: 8,10 THO1: 7,9.3 TPOX: 8 vWA: 17 |
| Name of Depositor： | AF Gazdar, JD Minna |
| Deposited As： | Homo sapiens |
| References： | Lai SL, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15: 225-232, 1995. PubMed: 7762988 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Johnson BE, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl. Cancer Inst. 81: 1223-1228, 1989. PubMed: 2569043 NCI-H660 was originally described as a small cell lung carcinoma PubMed: 2985257, subsequently it was correctly identified as an extrapulmonary small cell carcinoma originating in the prostate gland PubMed: 2569043, 7762988. The line was derived by A. F. Gazdar, H. K. Oie, J. D. Minna and associates from a lymph node metastasis taken from a patient prior to therapy. |
